Clinical trial
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
NCT00075244 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00075244 |
|---|---|
| Title | Alternative Dosing and Regimen of Replagal to Treat Fabry Disease |
| Official title | A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients With Fabry Disease |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Replagal |
| Enrollment | 25 |
| Start date | Jan 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Jan 7, 2004 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: